Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LanzaTech has demonstrated commercial success with its gas fermentation technology that converts industrial emissions into ethanol and other chemicals. Its first two commercial plants have produced over 40 million gallons of ethanol, offsetting significant CO₂ emissions. The company’s pipeline includes expansion into sustainable aviation fuel via its spinout LanzaJet and specialty chemicals through the new joint venture LanzaX. Over the next three years, global production capacity from its technology could reach around 200 million gallons annually with mitigation of up to one million tons of CO₂ per year.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on LanzaTech.